Related StoriesUS and German researchers synergy to advance quality control of human stem cellsNYSCF, CBR collaborate to customize creation of high-quality stem cell linesBlood stem cell self-renewal dependent on surroundingsIn this study, individuals randomized to receive stem cells could have their stem cells harvested from their own bone marrow in the operating area while they are under anesthesia. Following the bone marrow cells are harvested, Bruckner and Methodist cardiovascular surgeon Dr. Michael Reardon perform the bypass procedure. The cells are processed to separate stem cells from bone marrow simultaneously.The acquisition accelerates AbbVie's clinical and commercial presence in oncology, strengthening its already robust pipeline, and establishing its strong leadership placement in hematological oncology – an attractive and rapidly growing market, right now approaching$24billionglobally. The acquisition adds to AbbVie's already comprehensive pipeline and strong growth prospects. Under the terms of the deal, AbbVie will pay$261.25per share comprised of a mix of money and AbbVie equity. The transaction ideals Pharmacyclics at approximately$21 billionand was authorized by the Boards of Directors of both companies.